Most Read Articles
Jairia Dela Cruz, 3 days ago
Metabolic and bariatric surgery (MBS) leads to large and sustained reductions in, and even reversal of, multiple risk factors for future joint disease in adolescents with severe obesity and musculoskeletal pain, according to data from the Teen Longitudinal Assessment of Bariatric Surgery study.
Pearl Toh, 31 Dec 2019
Adding the neuraminidase inhibitor oseltamivir to usual care speeds up recovery from influenza-like illness by a day compared with usual care alone, with even greater benefits seen in older, sicker patients with comorbidities, according to the ALIC4E study.
23 Dec 2019
At a Menarini-sponsored symposium held during the Asian Pacific Society Congress, renowned cardiologist Prof John Camm provided the latest evidence for chronic stable angina with or without concomitant diseases, with a special focus on the antianginal agent ranolazine and combination therapies. The event was chaired and moderated by Dr Dante Morales from the University of the Philippines College of Medicine.
Pearl Toh, 6 days ago
Obeticholic acid significantly improves fibrosis and disease activity in patients with nonalcoholic steatohepatitis (NASH), a chronic liver disease currently with no approved therapy, according to an interim analysis of the landmark REGENERATE* study.

Valvular heart disease in Asia: Outcomes remain poor

Audrey Abella
18 Nov 2019
Dr Ding Zee Pin

Several Asian studies evaluating different types of valvular heart disease (VHD) reflected poor clinical outcomes, according to a presentation at ESC Asia 2019.

In the epidemiological OxValve Survive study (n=4,009), participants with moderate-to-severe VHD were found to have a two-fold reduction in survival. “This indicates that patients with even moderate VHD does not have a benign outcome,” stressed Dr Ding Zee Pin from the National Heart Centre Singapore. “[This] warrants further research … to understand the natural history of VHD and to identify those with progressive disease and when to intervene.”

A Japanese study on 182 individuals with primary moderate mitral regurgitation (MR) showed that those with moderate MR had a worse prognosis than patients who had mild or no MR (p<0.0001). “The predictor of poor outcome is paroxysmal atrial fibrillation,” said Ding. [ESC 2019, abstract P924]

Similar results were reflected in a collaborative study between the National Heart Centre Singapore and the University of London which evaluated moderate aortic stenosis (n=522; mean age 71 years, 54 percent male). Participants with more advanced disease had a poorer outcome than those without any extravalvular involvement. [ESC 2019, abstract P5582]

Among patients with infective endocarditis, mortality continues to rise despite contemporary management. “A review of recent literature … from Asia continuously shows that … the risk is higher among patients with nosocomial infection, those with large [medically treated] vegetations, and those who have undergone haemodialysis,” said Ding.

 

Does size matter?

A comparison of aortic annulus dimensions between Japanese and European participants showed the former to have a smaller and more eccentric aortic annulus than the latter. [AsiaIntervention 2016;2:49-56] In a Singaporean cohort, the iliofemoral vessel diameter is apparently smaller. [Int J Cardiol 2013;167:1373-1379] “[These findings suggest that] the smaller Asian size poses some challenge to [TAVI*],” said Ding.

In a Japanese TAVI registry comparing participants with and without a small annulus, those with a small annulus had a smaller indexed effective orifice area (1.10 vs 1.16 cm2), a higher mean pressure gradient (10.0 vs 8.5 mm Hg), and a lower frequency of moderate paravalvular leak (17.3 percent vs 24.4 percent; p<0.001 for all), noted Ding. Nonetheless, both arms had comparable 30-day mortality and stroke rates, suggesting that a small annulus did not influence short-term clinical outcomes. [ESC 2019; abstract P1788]

 

Help at your fingertips

A handheld echo scan may provide an opportunity for VHD screening and detection. In a rheumatic heart disease (RHD) screening in Borneo, Malaysia wherein 211 schoolchildren (mean age 10 years) participated, the device identified borderline RHD in 36 percent of the participants. “[This is] a significantly high incidence of borderline RHD among this cohort, suggesting that RHD continues to be prevalent in East Malaysia,” said Ding.

Despite the favourable short- and midterm mortality rates (1–3 percent [30 days] and 8–10 percent [1 year], respectively) observed in other larger Asian TAVI registries, [Circulation 2017;135:2013-2024; JACC Cardiovasc Interv 2016;9:926-933; Korean Circ J 2018;48:382-394] longer term outcomes from these registries are warranted to elucidate the long-term survival outcomes of VHD in Asia, said Ding.

 

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Jairia Dela Cruz, 3 days ago
Metabolic and bariatric surgery (MBS) leads to large and sustained reductions in, and even reversal of, multiple risk factors for future joint disease in adolescents with severe obesity and musculoskeletal pain, according to data from the Teen Longitudinal Assessment of Bariatric Surgery study.
Pearl Toh, 31 Dec 2019
Adding the neuraminidase inhibitor oseltamivir to usual care speeds up recovery from influenza-like illness by a day compared with usual care alone, with even greater benefits seen in older, sicker patients with comorbidities, according to the ALIC4E study.
23 Dec 2019
At a Menarini-sponsored symposium held during the Asian Pacific Society Congress, renowned cardiologist Prof John Camm provided the latest evidence for chronic stable angina with or without concomitant diseases, with a special focus on the antianginal agent ranolazine and combination therapies. The event was chaired and moderated by Dr Dante Morales from the University of the Philippines College of Medicine.
Pearl Toh, 6 days ago
Obeticholic acid significantly improves fibrosis and disease activity in patients with nonalcoholic steatohepatitis (NASH), a chronic liver disease currently with no approved therapy, according to an interim analysis of the landmark REGENERATE* study.